View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 11, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		10,684,516

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 2,801,092	$ 5,129,289
Prepaid expenses and deposits	129,028	51,150
Total current assets	2,930,120	5,180,439
Total assets	2,930,120	5,180,439
Current liabilities:
Accounts payable and accrued liabilities	2,301,161	1,508,312
Warrant liability	8,000	9,000
Promissory note	5,000	5,000
Total current liabilities	2,314,161	1,522,312
Total liabilities	2,314,161	1,522,312
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 41.7 million shares authorized, 10.6 million and 8.4 million shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	10,636	10,616
Additional paid-in capital	161,221,836	161,067,538
Accumulated deficit	(160,616,513)	(157,420,027)
Total stockholders' equity	615,959	3,658,127
Total liabilities and stockholders' equity	2,930,120	5,180,439
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,700,000	41,700,000
Common stock shares issued	10,600,000	8,400,000
Common stock shares outstanding	10,600,000	8,400,000
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Research and development	$ 1,599,550	$ 989,092
General and administrative	1,597,936	1,427,793
Total operating expenses	3,197,486	2,416,885
Loss from operations	(3,197,486)	(2,416,885)
Other income (expense):
Change in fair value of warrant liabilities	1,000	(3,000)
Net loss	$ (3,196,486)	$ (2,419,885)
Net loss per share, Basic and Diluted	$ (0.30)	$ (0.29)
Weighted average number of common shares outstanding	10,622,420	8,429,595

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Balance, Amount at Dec. 31, 2017	$ 3,658,127	$ 10,616	$ 161,067,538	$ (157,420,027)
Balance, Share at Dec. 31, 2017		10,615,724
Stock options exercised for cash, Amount	18,125	$ 10	18,115	0
Stock options exercised for cash, Share		10,416
Stock-based compensation, Amount	136,193	$ 10	136,183	0
Stock-based compensation, Share		10,042
Net loss	(3,196,486)	$ 0	0	(3,196,486)
Balance, Amount at Mar. 31, 2018	$ 615,959	$ 10,636	$ 161,221,836	$ (160,616,513)
Balance, Share at Mar. 31, 2018		10,636,182

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash Flows from Operating Activities:
Net loss	$ (3,196,486)	$ (2,419,885)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	(1,000)	3,000
Stock-based compensation	136,193	376,317
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(77,878)	(107,362)
Accounts payable and accrued expenses	792,849	224,252
Net cash used in operating activities	(2,346,322)	(1,923,678)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	18,125	0
Net cash provided by financing activities	18,125	0
Net decrease in cash	(2,328,197)	(1,923,678)
Cash at beginning of period	5,129,289	7,851,243
Cash at end of period	$ 2,801,092	$ 5,927,565

NATURE OF OPERATIONS

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1: Nature of Operations

TapImmune Inc. (the “Company” or “we”), a Nevada corporation incorporated in 1991, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2: Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2018 or for any future interim period. The condensed consolidated balance sheet at March 31, 2018 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2017, and notes thereto included in the Company’s annual report on Form 10-K filed on March 23, 2018.

LIQUIDITY AND FINANCIAL CONDITION

3 Months Ended

Mar. 31, 2018

Text Block [Abstract]

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of March 31, 2018, the Company had cash of approximately $2.8 million. Historically, the Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. The Company has no sources of revenue to provide incoming cash flows to sustain its future operations. The Company’s ability to pursue its planned business activities is dependent upon successful efforts to raise additional capital. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 23, 2018.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Recent Accounting Pronouncements Adopted in the Year

Compensation-Stock Compensation

In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company adopted ASU 2017-09 on January 1, 2018; the adoption of ASU 2017-09 did not have a material impact on its financial condition or results of operations, as the Company has not had any modifications to share-based payment awards. However, if the Company does have a modification to an award in the future, it will follow the guidance in ASU 2017-09.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 was to reclassify the Company's grant income as revenue.

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

On July 13, 2017, the FASB has issued a two-part ASU, No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.

The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

3 Months Ended

Mar. 31, 2018

Noncontrolling Interest [Abstract]

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Note 5: NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of net loss per share:

	Three Months Ended
	March 31,
	2018		2017
Numerator:
Net loss	$	(3,196,486)	$	(2,419,885)

Denominator:
Weighted average common shares outstanding		10,622,420		8,429,595

Net loss per share data:
Basic and Diluted	$	(0.30)	$	(0.29)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Three Months Ended
	March 31,
	2018		2017
Common stock options		439,000		417,000
Common stock purchase warrants		6,520,000		5,060,000
Potentially dilutive securities		6,959,000		5,477,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2018

Derivatives and Fair Value [Abstract]

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

Note 6: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018 and 2017 is as follows:

	March 31,			March 31,
	2018			2017
Stock price	$	3.38		$	4.49
Exercise price	$	1.20		$	1.20
Contractual term (years)		0.28			0.12 - 1.28
Volatility (annual)		69	%		67% - 79	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

	Fair value measured at March 31, 2018
	Quoted prices in active		Significant other observable		Significant unobservable		Fair value at
	markets		inputs		inputs		March 31,
	(Level 1)		(Level 2)		(Level 3)		2018
Warrant liability	$	-	$	-	$	8,000	$	8,000

	Fair value measured at December 31, 2017
	Quoted prices in active		Significant other observable		Significant unobservable		Fair value at
	markets		inputs		inputs		December 31,
	(Level 1)		(Level 2)		(Level 3)		2017
Warrant liability	$	-	$	-	$	9,000	$	9,000

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

⋅

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

⋅

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

⋅

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2018.

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2018:

	Warrant
	Liability
Balance - December 31, 2017	$	9,000
Change in fair value of warrant liability		(1,000)
Balance – March 31, 2018	$	8,000

STOCKHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

STOCKHOLDERS’ EQUITY

Note 7: STOCKHOLDERS’ EQUITY

2018 Common Stock Transactions

Exercise of Stock Options

In January 2018, Dr. John Bonfiglio exercised 10,416 shares of common stock pursuant to stock options at an exercise price equal to $1.74 per share.

Consulting Arrangements

During the three months ended March 31, 2018, the Company issued 10,042 shares of common stock as part of consulting agreements. The fair value of the common stock of approximately $33,000 was recognized as stock-based compensation in general and administrative expenses.

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Note 8: STOCK-BASED COMPENSATION

The Company recorded approximately $136,000 and $376,000 of stock-based compensation expense for the three months ended March 31, 2018 and 2017, respectively.

At March 31, 2018, the total stock-based compensation cost related to unvested awards not yet recognized was $262,000. The expected weighted average period compensation costs to be recognized was 0.47 years. Future option grants will impact the compensation expense recognized.

$33,000 and $103,000 of stock-based compensation expenses for the three months ended March 31, 2018 were included in general and administrative expenses and research and development expenses, respectively, on the condensed consolidated statements of operations.

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

Note 9: SUBSEQUENT EVENTS

Common Stock Purchase Agreement and Warrant Exercise Agreements

On May 14, 2018, the Company entered into a Common Stock Purchase Agreement with Eastern Capital Limited pursuant to which such investor has agreed to purchase 1,300,000 shares of common stock at a price per share of $2.40 providing gross proceeds to the Company of $3.12 million.

On May 14, 2018, certain institutional holders of outstanding warrants entered into Warrant Exercise Agreements with the Company that amends the exercise price of certain warrants to purchase an aggregate of 782,505 shares of common stock to $2.50 per share which will provide aggregate proceeds to the Company of approximately $2.0 million.

Closing of the Common Stock Purchase Agreement and the Warrant Exercise Agreements is subject to customary closing conditions and is expected to occur on May 18, 2018.

Financing Commitment

Mr. John Wilson, CEO of Marker, provided a written commitment on May 14, 2018 for additional financing to the Company of up to $1 million. Such commitment is subject to customary conditions none of which relate to the Agreement and Plan of Merger described below.

Agreement and Plan of Merger

On May 15, 2018, the Company entered into an agreement and plan of merger and reorganization with Marker Therapeutics, Inc., subject to shareholder approval and other terms and conditions set forth in the merger agreement.

At the effective time of the merger, each outstanding share of Marker’s common stock will be converted into the right to receive (i) shares of TapImmune’s common stock. Under the exchange ratio formulae in the merger agreement, as of immediately after the merger, the former Marker stockholders and the former TapImmune stockholders are each expected to own approximately 50% of the combined company, subject to certain assumptions (on a fully diluted basis) and prior to the contemplated issuance of shares in the financing that is expected to occur concurrently with the Merger. The final number of shares will be determined at the closing of the merger based on the number of shares of TapImmune common stock outstanding at the time of closing, and the final number of warrants will be determined at the closing of the merger based on the number of options and warrants of TapImmune outstanding at the time of closing. The number of warrants issuable to the Marker stockholders may be adjusted based upon certain conditions related to the terms of any additional financing closed concurrently with the merger.

The merger is subject to other customary closing conditions, including, among other things, the accuracy of the representations and warranties, subject generally to an overall material adverse effect qualification, compliance by the parties with their respective covenants and no existence of any law or order preventing the merger and related transactions. In addition, the merger is contingent upon TapImmune receiving commitments from third-party investors to purchase at least $25 million in equity securities of TapImmune, which equity financing would close contemporaneously with the closing of the merger.

The Merger Agreement contains certain termination rights and provides for the payment of a termination fee and reimbursement of certain fees and expenses of up to $2,000,000 by TapImmune to Marker upon termination of the Merger Agreement under specified circumstances.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

New Accounting Pronouncements

New Accounting Pronouncements

Recent Accounting Pronouncements Adopted in the Year

Compensation-Stock Compensation

Revenue from Contracts with Customers

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)

3 Months Ended

Mar. 31, 2018

Noncontrolling Interest [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of net loss per share:

	Three Months Ended
	March 31,
	2018		2017
Numerator:
Net loss	$	(3,196,486)	$	(2,419,885)

Denominator:
Weighted average common shares outstanding		10,622,420		8,429,595

Net loss per share data:
Basic and Diluted	$	(0.30)	$	(0.29)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Three Months Ended
	March 31,
	2018		2017
Common stock options		439,000		417,000
Common stock purchase warrants		6,520,000		5,060,000
Potentially dilutive securities		6,959,000		5,477,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2018

Derivatives and Fair Value [Abstract]

Valuation Methodology

	March 31,			March 31,
	2018			2017
Stock price	$	3.38		$	4.49
Exercise price	$	1.20		$	1.20
Contractual term (years)		0.28			0.12 - 1.28
Volatility (annual)		69	%		67% - 79	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

	Fair value measured at March 31, 2018
	Quoted prices in active		Significant other observable		Significant unobservable		Fair value at
	markets		inputs		inputs		March 31,
	(Level 1)		(Level 2)		(Level 3)		2018
Warrant liability	$	-	$	-	$	8,000	$	8,000

	Fair value measured at December 31, 2017
	Quoted prices in active		Significant other observable		Significant unobservable		Fair value at
	markets		inputs		inputs		December 31,
	(Level 1)		(Level 2)		(Level 3)		2017
Warrant liability	$	-	$	-	$	9,000	$	9,000

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the three months ended March 31, 2018:

	Warrant
	Liability
Balance - December 31, 2017	$	9,000
Change in fair value of warrant liability		(1,000)
Balance – March 31, 2018	$	8,000

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) $ in Millions	Mar. 31, 2018 USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 2.8

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Numerator:
Net loss	$ (3,196,486)	$ (2,419,885)
Denominator:
Weighted average common shares outstanding	10,622,420	8,429,595
Net loss per share data:
Basic and Diluted	$ (0.30)	$ (0.29)

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Common stock options	439,000	417,000
Common stock purchase warrants	6,520,000	5,060,000
Potentially dilutive securities	6,959,000	5,477,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 3.38	$ 4.49
Exercise price	$ 1.2	$ 1.2
Contractual term (years)	3 months 11 days
Volatility (annual)	69.00%
Risk-free rate	1.00%	1.00%
Dividend yield (per share)	0.00%	0.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Contractual term (years)		1 year 3 months 11 days
Volatility (annual)		79.00%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Contractual term (years)		1 month 13 days
Volatility (annual)		67.00%

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Warrant liability	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Warrant liability	0	0
Significant other unobservable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Warrant liability	8,000	9,000
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Warrant liability	$ 8,000	$ 9,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	3 Months Ended
	Mar. 31, 2018 USD ($)
Class of Warrant or Right [Line Items]
Balance	$ 9,000
Change in fair value of warrant liability	(1,000)
Balance	$ 8,000

STOCKHOLDERS’ EQUITY - Additional Information (Detail)	3 Months Ended
STOCKHOLDERS’ EQUITY - Additional Information (Detail)	Mar. 31, 2018 USD ($) $ / shares shares
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	10,416
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 1.74
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $	$ 33,000
Common shares issued	10,042

STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation	$ 136,193	$ 376,317
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 262,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	5 months 19 days
Selling, General and Administrative Expenses [Member]
Share-based Compensation	$ 103,000
Research and Development Expense [Member]
Share-based Compensation	$ 33,000

SUBSEQUENT EVENTS - Additional Information (Detail) - Subsequent Event [Member]	May 14, 2018 USD ($) $ / shares shares
Subsequent Event [Line Items]
Class of warrant or right, number of securities called by warrants or rights \| shares	782,505
Sales price per unit \| $ / shares	$ 2.50
Proceeds from Warrant Exercises	$ 2,000,000
Purchase Commitment, Remaining Minimum Amount Committed	25,000,000
Payment of termination fee	$ 2,000,000
Marker Therapeutics, Inc. [Member]
Subsequent Event [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	50.00%
Mr. John Wilson [Member]
Subsequent Event [Line Items]
Maximum financing amount	$ 1,000,000
Eastern Capital Limited [Member]
Subsequent Event [Line Items]
Units issued \| shares	1,300,000
Sales price per unit \| $ / shares	$ 2.40
Units issued, value	$ 3,120,000